While neither RNA nor protein levels in this heterogeneous collection of treatment-naïve and pre-treated patient tumors are as high as that seen in HER2+ breast cancer (contextualized in Fig. S2B, C), nonetheless they consistently show modest increase in total HER2 RNA and protein levels in MutL− ER+/HER2− patient tumors. Here, ESR1 is linked to breast carcinoma.